CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00754494
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:46.997557+00:00
Published At: 2015-01-06T00:00:00+00:00
Record Updated At: 2015-01-06
Results Posted At: 2015-01-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adenomatous Polyp", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage I Colon Cancer", "Stage I Rectal Cancer", "Stage IIA Colon Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-01-06"
protocolSection.identificationModule.nctId: "NCT00754494"
protocolSection.identificationModule.officialTitle: "A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-01-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.